In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
|Articles|January 29, 2008
Clot-dissolving agent gains additional shelf life
ImaRx Therapeutics' urokinase gains an additional 20 months of expiration dating
Advertisement
ImaRx Therapeutics' urokinase has received an additional 20 months of expiration dating. This means the clot buster from the Tucson, Ariz., firm's most recent lot will have a prolonged shelf life. The thombolytic is indicated for the treatment of acute massive pulmonary embolism.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Advertisement
Advertisement
Trending on Drug Topics
1
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
2
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
3
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
4
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
5